MDT Medtronic Plc

2020 Catalyst Award Winner Medtronic Hires Chief Inclusion and Diversity Officer

2020 Catalyst Award Winner Medtronic Hires Chief Inclusion and Diversity Officer

DUBLIN, Feb. 24, 2020 (GLOBE NEWSWIRE) --   (NYSE:MDT), the global leader in medical technology, is hiring its first Chief Inclusion and Diversity Officer, underscoring its continued focus and significant investment in inclusion and diversity as a business priority.

Sally Saba, M.D., will assume the newly created position effective March 2, 2020. In this role, she will be responsible for delivering a comprehensive global inclusion and diversity strategy and strengthening Medtronic’s inclusive culture and employment brand, ensuring the company is well-positioned to attract and retain top talent. Saba will report to Carol Surface, Chief Human Resources Officer.

“I am proud of the progress we’ve made, including our recent Catalyst recognition, and am excited to have Sally on board to continue to build on our strong foundation and help us reach new levels of inclusion, diversity, and equity at Medtronic,” said Carol Surface, Chief Human Resources Officer. “Her thought leadership, authenticity, and passion for the Mission and healthcare make her uniquely suited to lead our efforts into the future.”

“My philosophy is to listen and learn, and bring people along to co-create,” said Saba. “When employees participate in shaping the future of who they want to be as a company, they are more engaged, and we collectively move faster. Equity, inclusion and diversity isn’t one big thing you do – it’s a million little things that we all do every day.”

Most recently, Saba was the Vice President of Equity, Inclusion, and Diversity at Kaiser Permanente Health Plan and Hospitals, the largest non-profit integrated healthcare system in America. In her time there, she spearheaded key initiatives, including a high-profile supplier diversity program. Before joining Kaiser, Saba served in leadership roles at global telecom company Vodafone.

Saba holds a medical degree from Cairo University and an MBA from École Supérieure Libre des Sciences Commerciales Appliquées in Paris. Learn more about Sally Saba on the .

About Medtronic

Medtronic plc (), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-



Erika Winkels

Public Relations

Ryan Weispfenning

Investor Relations

EN
24/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Prior Breakout Level DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. While the dust has yet to settle, the good news is that the selloff has been largely contained to these AI-linked stocks. The rest of the market did not seem to care; the equal-weighted S&P 500 was roughly flat yesterday. Additionally, market dynamics remain healthy, with Treasury yields, the U.S. dollar (DXY), and WTI crude oil continuing to move lower, and...

Medtronic, Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong product diversification, offset by its large payouts to shareholders.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch